Skip to main content
Premium Trial:

Request an Annual Quote

It Appears They're in the Market for Something Tougher than a Time-Out

The Wall Street Journal reports that Congress members are pushing to transform the US FDA "by giving it broad powers to levy fines, order drug recalls and restrict drug-industry advertising," the article says. "The lawmakers say an FDA restructuring should build a much taller wall between the agency and the industry it regulates." The changes, if they happen, aren't expected to take place until next year.

 

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.